Longevity science attracts significant research interest, focusing on extending lifespans while preventing disease and age-related decline. Multiple approaches exist, including genetic factors present at birth and dietary choices throughout life. An international group of scientists now argues that longevity studies and interventions should begin at the earliest possible stages, including before birth. In a paper published in Nature Health, the team advocates creating a life-course consortium named PROSPER, which stands for Pregestational and Pediatric Research for Optimal Healthspan and Early-life Resilience. The core claim is that most longevity work targets later adulthood, after substantial bodily damage has accumulated. The authors note that healthy longevity medicine has mainly addressed adult groups, applying interventions only after years of molecular and cellular aging changes. This strategy misses an important early opportunity. Although prior studies have examined childhood influences on lifespan, the field lacks integrated approaches for tracking aging markers across all life stages. For instance, adult aging indicators may carry different meanings in children, highlighting inconsistencies a consortium could resolve. The researchers call for expanded longevity studies involving younger participants. They stress that biological age in early life indicates developmental balance and resilience rather than accumulated harm, requiring tailored models, markers, and frameworks. The proposal also introduces the concept of peakspan, referring to periods of optimal performance that occur at various points in life. This perspective considers not only total years lived or years without disease, but also the share of life spent at prime capacity. The effort would combine multiomics information, clinical data, and functional assessments across developmental phases to build longitudinal biological paths for better risk prediction and interventions. It also aims to create age-specific diagnostic and treatment approaches for routine obstetric and pediatric care, moving from reactive treatment to proactive optimization. The idea remains preliminary with limited specifics. If established, PROSPER would coordinate clinical guidelines, trials, and data integration in novel ways. The proposing scientists are longevity specialists, and acceptance by the community could yield broader discoveries applicable at any age. The authors conclude that such a consortium would enhance research and practice by connecting previously separate disciplines to address aging from its earliest origins to later clinical effects. The work appeared in Nature Health.
